The Annals Take our Readership Survey!
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     

The Annals of Pharmacotherapy: Vol. 29, No. 11, pp. 1164-1167.
© 1995 Harvey Whitney Books Company.
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Welty, D.
Right arrow Articles by Rothstein, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Welty, D.
Right arrow Articles by Rothstein, J.

Research Articles

Potential treatment of amyotrophic lateral sclerosis with gabapentin: a hypothesis

DF Welty, GP Schielke, and JD Rothstein

OBJECTIVE: To provide the biochemical rationale for the use of the new anticonvulsant agent gabapentin as a treatment for amyotrophic lateral sclerosis (ALS). BACKGROUND: ALS is a neuropathologic disorder of the central nervous system characterized by a progressive loss of upper and lower motor neurons. Although the etiopathology of ALS is incompletely known, it is hypothesized that glutamatergic neurotransmission is related to neuropathology. Glutamate is an excitatory amino acid neurotransmitter that is cytotoxic when overexpressed at synaptic terminals, probably through a calcium-related mechanism. The concentration of glutamate in cerebrospinal fluid is increased in patients with ALS. The increased extracellular concentrations of glutamate may be caused by a decreased capacity of glutamate transport in brain tissue and/or abnormal glutamate metabolism. Recent success with the glutamate release inhibitor riluzole in well-controlled clinical trials supports the excitotoxic mechanism of neuropathology in patients with ALS. POTENTIAL TREATMENT FOR ALS: Gabapentin has demonstrated neuroprotective properties in a model of chronic glutamate toxicity in vitro. Although the neuroprotective mechanism of action of gabapentin is currently unknown, it is hypothesized here that gabapentin decreases the rate of formation of glutamate derived from the branched-chain amino acids (BCAAs) leucine, isoleucine, and valine. The proposed decrease in formation of glutamate from BCAAs may decrease the pool of releasable glutamate and therefore compensate for diminished glutamate uptake capacity and/or abnormal glutamate metabolism in patients with ALS. CONCLUSIONS: Based on this rationale, it is proposed that gabapentin may provide a beneficial effect in the treatment of patients with ALS.


This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
M. Goto, I. Miyahara, K. Hirotsu, M. Conway, N. Yennawar, M. M. Islam, and S. M. Hutson
Structural Determinants for Branched-chain Aminotransferase Isozyme-specific Inhibition by the Anticonvulsant Drug Gabapentin
J. Biol. Chem., November 4, 2005; 280(44): 37246 - 37256.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
M. D. Caramia, M. G. Palmieri, M. T. Desiato, C. Iani, A. Scalise, S. Telera, and G. Bernardi
Pharmacologic reversal of cortical hyperexcitability in patients with ALS
Neurology, January 11, 2000; 54(1): 58 - 58.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
J. Davoodi, P. M. Drown, R. K. Bledsoe, R. Wallin, G. D. Reinhart, and S. M. Hutson
Overexpression and Characterization of the Human Mitochondrial and Cytosolic Branched-chain Aminotransferases
J. Biol. Chem., February 27, 1998; 273(9): 4982 - 4989.
[Abstract] [Full Text] [PDF]


homecopy help contact us subscription past issues search current issue
Copyright © 1995 by Harvey Whitney Books Company.